Stroke Prevention With DOACs
Cardiology Pharmacist’s Insights on Stroke Prevention in NVAF With Evidence-Based DOAC Therapy

Released: April 25, 2022

Expiration: April 24, 2023

Stephanie Dwyer Kaluzna
Stephanie Dwyer Kaluzna, PharmD, BCCP

Activity

Progress
1
Course Completed

This podcast is the second in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, cardiology pharmacist Stephanie Dwyer Kaluzna, PharmD, BCCP, reviews key literature and guideline recommendations for stroke prevention in patients with NVAF. Dr Dwyer Kaluzna discusses the most recent evidence for prescribing, dosing, and monitoring direct oral anticoagulants (DOACs); using the risk-screening tools HAS-BLED and CHA2DS2-VASc to design patient-specific pharmacotherapy plans; and the use of DOACs in special patient populations, including older patients, patients with end-stage renal disease, and patients with low or high body weights.